| Name | Title | Contact Details |
|---|
InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany as well as Ann Arbor, Michigan. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”.
Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.
Laser Pharmceuticals is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Akari Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5). Its lead drug, Covers...